# The Clorox Company (CLX) — Financial Analysis

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-13  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/CLX/thesis · /stocks/CLX/memo

## Financial Snapshot

---
ticker: CLX
step: 04
generated: 2026-05-13
source: quick-research
---

### The Clorox Company (CLX) — Financial Snapshot

#### Income Statement Summary

| Metric | FY2022 | FY2023 | FY2024 | YoY |
|--------|--------|--------|--------|-----|
| Revenue | $7.10B | $7.39B | $7.09B | -4.0% |
| Gross Margin | ~38% | ~37% | ~44% | |
| Operating Margin | ~9% | ~3% | ~6% | |
| Net Income | $462M | $149M | $280M | +88% |
| EPS (diluted) | ~$3.72 | ~$1.20 | ~$2.25 | +88% |

*FY2022–2023 were deeply impacted by commodity cost inflation (resins, diesel, pulp) and the catastrophic ERP implementation failure that caused supply-chain breakdowns and a 17% organic sales decline at peak disruption. FY2024 showed recovery — gross margin expanded to ~44% as commodity costs normalized and pricing actions flowed through. FY2025 revenue reached $7.1B with EPS recovery continuing; Health & Wellness segment grew 8.5% YoY.*

#### Cash Flow & Balance Sheet (FY2024)

| Metric | Value |
|--------|-------|
| Operating Cash Flow | ~$800M |
| Free Cash Flow | ~$650M |
| Capital Expenditures | ~$150M |
| Cash & Equivalents | ~$350M |
| Total Debt | ~$2.8B |

*FCF recovered strongly as gross margins normalized. Dividend currently $1.22/quarter ($4.88/year), yielding ~4.8% — maintained through the ERP crisis, signaling management confidence. Debt elevated but manageable given FCF generation.*

#### Key Ratios (approximate)
- P/E: ~30–35x (trailing, on recovering EPS) | EV/EBITDA: ~18x | Dividend Yield: ~4.8%
- Revenue Growth (FY2024): -4.0% | FY2025: ~flat to slight positive
- Return on Invested Capital: ~35%+ (brand moat indicator)
- Bleach market share: ~61% U.S.

#### Growth Profile
Clorox is a slow-growth staples compounder under normal conditions (2–4% organic growth) disrupted by two major shocks: FY2022 commodity inflation and FY2023–2024 ERP disaster. The recovery path involves: (1) fill rate normalization (target 92%+ by early 2026), (2) gross margin recovery toward 44–45% as commodity headwinds ease, (3) market share recapture in categories where stockouts caused switching. FY2025 and FY2026 should show above-trend EPS growth driven by recovery, not fundamental acceleration. The structural long-term thesis is brand moat + pricing power in essential categories.

#### Forward Estimates
- FY2026: Revenue growth of 2–4% organic; EPS recovery toward $6–7 adjusted as margins stabilize
- Dividend: $4.88/year (FY2025); consistent annual increases expected
- Analyst consensus: Mixed — majority Hold/Neutral; some Underweight (JPMorgan downgrade April 2026 citing private-label pressure and consumer weakness)
- Private-label risk: Key watch item — share erosion in cleaning products vs. store brands at Walmart/Target

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/CLX/fundamental

## Navigation

- Overview: /stocks/CLX
- Financials (this page): /stocks/CLX/financials
- Thesis: /stocks/CLX/thesis
- Investment Memo: /stocks/CLX/memo
- Coverage universe: /stocks